Financials data is unavailable for this security.
View more
Year on year Enanta Pharmaceuticals Inc 's revenues fell -8.07% from 86.16m to 79.20m. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from a loss of 121.76m to a larger loss of 133.82m.
| Gross margin | -- |
|---|---|
| Net profit margin | -160.27% |
| Operating margin | -170.74% |
| Return on assets | -25.80% |
|---|---|
| Return on equity | -59.64% |
| Return on investment | -30.05% |
More ▼
Cash flow in USDView more
In 2023, Enanta Pharmaceuticals Inc increased its cash reserves by 86.31%, or 41.39m. Cash Flow from Financing totalled 198.13m or 250.15% of revenues. In addition the company used 103.15m for operations while cash used for investing totalled 53.58m.
| Cash flow per share | -5.34 |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 7.03 |
|---|---|
| Tangible book value per share | 7.03 |
More ▼
Balance sheet in USDView more
| Current ratio | 4.92 |
|---|---|
| Quick ratio | -- |
| Total debt/total equity | 0.0096 |
|---|---|
| Total debt/total capital | 0.0095 |
More ▼
Growth rates in USD
Year on year, growth in earnings per share excluding extraordinary items dropped -7.99%.
| EPS growth(5 years) | -- |
|---|---|
| EPS (TTM) vs TTM 1 year ago | 13.43 |
